
PRESS RELEASE**FOR IMMEDIATE RELEASE****Media Contact**

Jeremy D. Ollerenshaw, Ph.D.
Executive Director, Neurobiology Foundation, Inc.
ollerenj@neurobiologyfoundation.org
770-337-2390

The NeuroBiology Foundation and Lena Biosciences Sign Letter of Intent for Collaborative Development

ATLANTA, GA, November 1, 2015 – The NeuroBiology Foundation and Lena Biosciences, Inc. announced today the signing of a Letter of Intent for collaborative development and commercialization of products that will be successful in revealing new therapeutic targets and ultimately be used in diagnosis or treatment assisting those with, or affected by mental illnesses.

About Lena Biosciences:

Lena Biosciences is a biotechnology company developing and selling three-dimensional (3D) cell culture products. The company has pioneered Spot-a-Culture and Spot-a-Drug Platform Technologies for tissue fingerprinting in life sciences and pharmaceutical testing. These tissue equivalent models in the rapidly expanding 3D cell culture and ADME/Tox screening arena have been validated and enable researchers to grow constructs, test compounds, and assess functional outcomes with improved physiological relevance. In part, the technology originated in the laboratories of the Georgia Institute of Technology with which the company maintains a strong collaboration. Lena Biosciences is backed by research funded by the National Institutes of Health as a small business grant, and the Georgia Research Alliance Venture Lab.

To learn more about Lena Biosciences, Inc. please visit their website at www.lenabio.com

About the NeuroBiology Foundation:

The NeuroBiology Foundation is a non-profit tax-exempt 501c(3) organization that is focused on clearly understanding the neuroscience of structural and molecular abnormalities in psychotic illnesses such as schizophrenia and bipolar disorder. Using this knowledge, precise therapeutic targets can be revealed or the development of improved management and cures for these illnesses. The Foundation works to partner with innovative technology companies, academic scientists and clinicians to facilitate its work in serious mental illness.

###